about | Maps & Directions | contact | admissions | faculty | alumni & development | library | Tech Support Center | dean's office | Policies & Procedures

Center for Substance Abuse Research logo

center for substance abuse research

Core Center of Excellence

“Center on intersystem regulation by drugs of abuse”
NIH/NIDA P30 DA13429
Program Director/Center PI: Unterwald


This Core Center of Excellence supports and enhances research related to drugs of abuse and addiction. Eight Core facilities are supported by this grant and serve as a resource to the general scientific community. The Cores are briefly described below. Please contact the Core Director for further information about the services provided.




Ellen M. Unterwald, PhD, Core Director

ellen.unterwald@temple.edu, 215-707-1681
Lynn Kirby, PhD, Co-Investigator

lynn.kirby@temple.edu, 215-707-8556


The Animal Core serves as a centralized resource that provides mice with genetic deletions or mutations to the members of the Center, other research groups at the university, and the general scientific community. Genetically engineered mice are bred and maintained at the Central Animal Facility of Temple University, thus ensuring consistent background strains across studies, appropriate control mice, and ready access to mice of the age and sex necessary for experimentation. In-house breeding and use of the same animal strains by multiple investigators enhances collaborative studies and increases scientific synergy.


The Animal Core provides the following services:

  • Breeding and maintenance of animals that have targeted gene deletions or express transgenes. Mouse lines currently being bred in the Animal Core include opioid receptor knockout mice (MOPR, KOPR, DOPR), cannabinoid receptor knockout mice (CB1, CB2, CB1/CB2), and chemokine receptor knockout mice (CCR5).
  • Genotyping of the animals carried out in collaboration with the Molecular Core.
  • Phenotyping of the animals characterized together with the Integrative Pharmacology Core.



Lee-Yuan Liu-Chen, PhD, Core Director

lee-yuan.liu-chen@temple.edu, 215-707-4188


The Biochemical Pharmacology Core provides the following services:

  • Receptor binding: opioid receptors, dopamine receptors and nicotinic receptors. We will develop assays for others when necessary.
  • Receptor autoradiography: opioid receptors. We will develop others when necessary.
  • Assessment of receptor activation by determination of cAMP level, [35S]GTPÿS binding, and p44/42 MAP kinase phosphorylation
  • Protein gel electrophoresis and immunoblotting
  • Assessment of suitability of receptor antibodies for immunoblotting: opioid receptors initially. We will do others when needs arise.



Toby K. Eisenstein, PhD, Core Director

toby.eisenstein@temple.edu, 215-707-3585


The Cell and Immunology Core provides the following services:

  • Basic tests of immune function for mouse, human and rat cells including:
    - Response of lymphocytes to mitogens
    - Assay of Natural Killer (NK) cell activity
    - Capacity for in vitro antibody formation
    - Mixed Lymphocyte Reaction (MLR)
  • Assays for levels of cytokines, chemokines, and neuropeptides using ELISA multiplex assays such as the Cytometric Bead Array assay
  • Separate cells by magnetic bead separation
  • Analyze expression of surface markers on cells using Flow Cytometry (FACS)
  • Perform mycoplasma testing of cell lines



Ronald J. Tallarida, PhD, Core Director

ronald.tallarida@temple.edu, 215-707-3243

Ellen M. Unterwald, PhD, Director, CSAR
ellen.unterwald@temple.edu, 215-707-1681


There is a pressing need for information on the effects of combinations of drugs of abuse. The CSAR Core Center for Excellence at Temple University, through its Center on intersystem regulation by drugs of abuse (NIH/NIDA, P30) has addressed this need by the establishment of this database core. Dr. Ronald J. Tallarida, a professor and member of the CSAR group at Temple, directs this core and has studied and published extensively in the area of drug combinations. That body of work includes new experimental and mathematical methodologies and numerous experimental projects with drug combinations. That effort has been supported partly through Dr. Tallarida’s past NIH and industrial grants and through the Center’s P30 grant. Many drug combinations are well known for their approved use as well as their use on the street, (e.g., fentanyl + cocaine, heroin + methamphetamine, etc, and extensive combinations that involve alcohol or marijuana). This core of the Center’s P30 grant has supported the development of a database that identifies relevant articles from the broad literature of laboratory-based studies and human use that include drug combinations of special relevance. The drug combinations include the legitimate medical use as well as common “street combinations”. The main objective is to search for and identify publications that lead to classifying interactions as synergistic, sub-additive or simply additive. Included in this body of work are several review-type publications by Dr. Tallarida et al that illustrate the computational methodology and experimental design guidelines. These are published papers that can be used by all researchers for quantitatively assessing drug interaction and distinguishing synergism and sub-additivity from simply additive interactions. The review-type articles are contained in one of the two databases and are appropriately marked.


There are two databases. One is termed internal and that refers to publications authored or co-authored by Dr. Tallarida. Many of these co-authored papers are with members of CSAR and all of Dr. Tallarida’s reviews are included. The external database refers to papers we identified from the literature search that deal with combinations (among drugs of abuse) and the quantitative assessment of interactions. These were identified through an extensive literature search. All papers in both databases were read and brief summaries of the most important findings are provided here along with the reference. In some cases (e.g., publications from the Journal of Pharmacology & Exp. Ther) we obtained permission to include the published abstract. Each database has a table of contents that identifies the reference with a number. In almost all cases we also provide the PubMed identifier for ease in locating the full article and/or its abstract.




Alan Cowan, PhD, Core Director

alan.cowan@temple.edu, 215-707-4110
Ronald J. Tallarida, PhD, Co-Investigator
Martin W. Adler, PhD, Co-Investigator
Ellen B. Geller, Co-Investigator


The Integrative Pharmacology Core offers pharmacological testing services for the following endpoints in mice and/or rats:

  • Irwin neurological screen of overt behavior
  • Rotorod trials for motor coordination
  • Automatic monitoring for ambulation and stereotypes
  • Exploratory behavior in the Y-maze
  • Assessment of anticonvulsant activity
  • Analgesic/tolerance tests for acute, persistent and incisional pain
  • Anti-inflammatory activity (carrageenan test)
  • Antipruritic activity
  • Physical dependence/withdrawal
  • Diuresis
  • Body and brain temperature measurement
  • Gastrointestinal transit
  • Tests of anxiety- and depression-like behaviors
  • Assessment of drug reward



Thomas J. Rogers, PhD, Core Director

thomas.rogers@temple.edu, 215-707-3215


This core facility provides a full range of molecular services to investigators with research interests which are relevant to drug abuse. The services provided include:

  • Molecular cloning and expression vector design and construction
  • Determination of sequences and restriction nuclease sites when necessary
  • Analysis of gene expression using northern blot analysis, RNAse protection analysis, RT-PCR, and related techniques
  • Analysis of gene promoter/enhancer function by reporter analysis
  • Analysis of transcription factor activity by array screen, ChIP analysis, electrophoretic mobility shift analysis (EMSA), or nuclear run-on assays
  • Creation of transcription/translation modulators including custom design of antisense oligonucleotides, interfering RNA design and construction, and the preparation of dominant-negative or inactive forms of gene products
  • Genotyping services required for the Animal Core.are also carried out by the Molecular Core.